



# Pharmacy & Therapeutics Committee

## Meeting Minutes

Thursday, February 17, 2022  
7:00 a.m. to 8:45 a.m.  
Google Meet

### Committee Members Present:

Cole Sloan, PharmD	McKay Robinson, PharmD
Bryan Larson, PharmD	Michelle Hofmann, MD
Clayton Grace, RPh	Susan Siegfried, MD

### Committee Members Excused:

Christopher Valentine, MD	Clinton Sheffield, MD
---------------------------	-----------------------

### Dept. of Health/Div. of Health Care Financing Staff Present:

Bryan Larson, PharmD	Ngan Huynh, PharmD
Joe Busby, RPh, MBA	Stephanie Byrne, PharmD
Luis Moreno, PharmD	Andrea Rico, CPhT
Jennifer Strohecker, PharmD, Pharmacy Director	Spencer Miller, CPhT

### University of Utah Drug Regimen Review Center Staff Presenter:

Monet Luloh, PharmD

### Other Individuals Present:

Anthony Duca, Incyte	Lindsey Walter, Novartis
Brandon Yip, Sanofi-Aventis	Lisa Angelos, Change Healthcare
Bret Ferguson, Pfizer	Lisa Ashton, Johnson & Johnson
Charlie Lovan, AbbVie	Mariola Vazquez, LEO Pharma
Gabriela Gutierrez, Pfizer	Rob Booth, AbbVie
Jason C Bott, Lilly	Samantha Eshelman, Select Health
Kelvin Yamashita, Sanofi-Aventis	Tony Patterson, Assistant Attorney General
Kevin Hinthorne, LEO Pharma	Valerie Gonzales, U of U DRRC
Lauren Heath, U of U DRRC	Brian and Holly W.
Lovell Robinson, AbbVie	

(Note: 3 Phone Numbers Unidentified)

# Pharmacy & Therapeutics Committee

## Meeting Minutes

Meeting conducted by: Cole Sloan

---

1. Training: Tony Patterson conducted training for the Open and Public Meeting Act.
2. Bryan Larson announced a quorum at 7:21AM.
3. Review and Approval of November Minutes: Cole Sloan made a motion to approve the minutes from November. Clayton Grace seconded the motion. All in favor, none opposed, no abstention, motion passed.
4. Drug Utilization Review (DUR) Board Update: Ngan Huynh presented the Board Update. The board met in January to review Lupus Nephritis and recommended to not require prior authorization for Benlysta and Lypkynis. The Board also met in February to review codeine use in children. Board recommended updating age limit in cough, cold, and pain with codeine products to be in alignment with FDA changes. The March DUR meeting has been cancelled and the next meeting will be determined.
5. Non-steroidal treatments for atopic dermatitis: Monet Luloh presented from the University of Utah. No explicit definition of mild, moderate, or severe disease is declared in US guidelines. Usually topical therapies are utilized for mild to moderate disease. Systemic treatments are reserved for more severe cases. There are three different classes of FDA approved topical agents; calcineurin inhibitors, phosphodiesterase inhibitors, and Janus Kinase (JAK) inhibitors. All topicals are approved for pediatric and adult patients. Approved systemic agents include Interleukin (IL) antagonists and JAK inhibitors. Among these, there are injectables dupilumab (IL-4 antagonist) and tralokinumab (IL-13 antagonist) and oral medications abrocitinib and upadacitinib (both JAK inhibitors).
6. Public Comment:
  - a. Gabriela Gutierrez presented on Cibinqo for Pfizer.
  - b. Brandon Yip presented on Dupixent for Sanofi-Aventis.

# Pharmacy & Therapeutics Committee

## Meeting Minutes

- c. Mariola Vasquez presented on Adbry for LEO Pharma.
- d. Charlie Lovan presented on Rinvoq for AbbVie.

### 7. Committee Discussion:

- a. Committee discussed data on combining various medications or situations that these medications should not be combined. JAK inhibitors should not be combined. Topical corticosteroids can be used for flares when they arise with systemic medications. Discussed combinations of topical therapies.
- b. Cole Sloan made a motion to consider at least one non-steroidal topical product, FDA approved, for pediatric atopic dermatitis as preferred on the PDL. McKay Robinson seconded. All in favor, none opposed, no abstention, motion passed. Michelle Hoffman was not present for this vote.
- c. Bryan Larson made a motion that all of the nonsteroidal agents for atopic dermatitis are appropriate for inclusion on the preferred drug list, without specifying preferred and nonpreferred, and not limited by route or administration. Susan Siegfroid seconded. All in favor, none opposed, no abstention, motion passed. Michelle Hoffman was not present for this vote.
- d. Susan Siegfroid made a motion to have a grandfathering clause for those already on a particular medication within this drug class; that they not be forced to take something else if the PDL changes from what it is currently prescribed. Clayton Grace seconded. All in favor, none opposed, no abstention, motion passed. Michelle Hoffman was not present for this vote.

8. Public Meeting Adjourned: Cole Sloan motioned to close the meeting. Bryan Larson seconded the motion. All in favor, none opposed, no abstention, motion passed. Michelle Hoffman not present.

9. Next meeting is scheduled for May 19, 2022 on the topic of Colony Stimulating Factors.